LDHA and prostate carcinoma: circARHGAP29 interacts with IGF2BP2 to improve lactate dehydrogenase A (LDHA) mRNA stability, thereby enhancing tumor cell glycolysis; the molecule provides a promising therapeutic target for docetaxel-resistant prostate cancer [24].